ArticleTranslational lung cancer research2025
Shared genetics of lung cancer and type 2 diabetes: a large-scale genome-wide cross-trait analysis.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer (LCA) and type 2 diabetes (T2D) are major global health burdens, with accumulating evidence suggesting a genomic link. This study systematically investigates the shared genetic architecture between LCA subtypes [small cell lung cancer (SCLC), lung squamous cell carcinoma (LUSC), lung adenocarcinoma (LUAD)] and T2D using large-scale genome-wide association studies (GWAS). Methods: We conducted genome-wide genetic correlation analyses using linkage disequilibrium score regression (LDSC) and local genetic correlation analyses via heritability estimation from summary statistics (HESS). Pleiotropic variants were identified using the pleiotropic analysis under composite null hypothesis (PLACO), and functional annotation was performed with functional mapping and annotation of genetic associations (FUMA). Pathway and Gene Ontology (GO) analyses were carried out using Kyoto Encyclopedia of Genes and Genomes (KEGG) and GO, and tissue-specific enrichment patterns were evaluated with LDSC for the specific expression of genes analysis (LDSC-SEG). Results: Our analysis revealed significant positive genetic correlations between T2D and LCA subtypes, particularly in SCLC and LUSC. Genome-wide genetic correlation analyses indicated the strongest correlation between LCA and T2D. Local genetic correlation analysis identified several genomic regions with suggestive significance. A total of 50 independent genomic risk loci were identified as pleiotropic loci, involving 34 unique chromosomal regions. Notably, the 9p21.3 region (CDKN2B-AS1) was identified in all pairwise trait analyses. Functional annotation highlighted deleterious variants in genes such as Conclusions: This study provides robust evidence of a shared genetic architecture between LCA subtypes and T2D, highlighting potential therapeutic targets. Future research should focus on validating these findings in larger cohorts and exploring the functional roles of the identified genes in the co-occurrence of these conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.